 Life Science Investor Mandates
(Aug. 24
- Aug. 30)
|
|
|
|
|
Looks Worldwide for New Platforms in Cardio, Oncology, Metabolic Diseases, and More
|
Invests in Oncology, GI and CNS Drugs and New Platform Technologies
|
|
Makes Strategic Investments in Dental Technologies
|
|
Focuses on Early Stage Biotech, Personalized Medicine and Novel Devices
|
|
Click to see investors that are a fit for your product and stage of development
|
|
Click here if you are a service provider and want to see a list of funded life science companies that are a fit for you
|
|
Click here if you want to receive free, targeted early stage dealflow for your life science investment firm
|
|
|
We are pleased to announce our forty finalists to compete in the Innovation Challenge at LSN's 2017 RESI in Boston on September 26th. From a pool of over 100 applicants, the LSN Scientific Review Committee has selected a mixture of healthcare IT, diagnostic, therapeutic, and medical device companies, a portion of which have received funding from NIH or partnered with Techstars-Cedars Sinai. The quality of these companies should not go unnoticed, as we have seen nearly 50% of Innovation Challenge finalists from previous RESI events receive funding within one year of their debut...
|
The majority of companies that we see at LSN have already secured some SBIR/STTR grant funding and/or have raised seed capital, generally from friends, family and angels (FFA). This funding tends to be used to cover incorporation fees, initial IP costs as well as some additional technical development to further de-risk their technology, making it more attractive for investors in a larger round.
What comes next, and when most companies come to LSN, is referred to as the "Valley of Death". This is the area between FFA and significant VC investment, a gap that many companies fail to bridge. If you are plugged into daily news on biotech and life science venture rounds (which I would highly recommend for any fundraising entrepreneur) it is not uncommon to see Series A's to the tune of $20 million or more...
|
 |
Personalized medicine, NGS and new biomarkers promise a new age of tailored, targeted medical care. However, diagnostics is a notoriously challenging landscape for both entrepreneurs and investors. Through our research and outreach, LSN has found that many investors are still looking at diagnostic opportunities, with some focusing exclusively or primarily on the sector. At RESI Boston, we've gathered five experienced investors from both the venture and corporate worlds to explain what they're looking for in the sector and how entrepreneurs can improve their odds of finding funding for their diagnostic business.
Moderated by Tom Miller, Managing Director, GreyBird Ventures, the panelists are:
- Alex Dewinter, Director, GE Ventures
- Wouter Meuleman, (Director of Investments, Illumina Ventures
- Diana Saraceni, Founder & Managing Director, Panakes Partners
- Adam Lessler, Vice President, Canepa Healthcare
|
|
|
